The Radiation Therapy Oncology Group (RTOG) is the leading multicenter and multidisciplinary research organization systematically testing novel radiotherapy (RT) approaches against cancer and pursuing fully integrated translational research to enhance this effort. The group will build on its outstanding scientific accomplishments in the current funding period to conduct research based on three fundamental initiatives: 1. Physical Targeting: RTOG will implement and test advances in imaging and high-precision RT planning and delivery technologies in clinical trials. 2. Molecular Targeting: Combined with RT: RTOG will design and conduct hypothesis-driven trials testing the integration of novel molecular targeted anti-cancer agents with optimized RT or chemo-RT. 3. Translational Research: RTOG will implement powerful biostatistical and medical informatics approaches to its unique and inter-linked clinical, biophysical, biologic, and outcomes databases that will faciliate hypothesis-driven analyses of these resources. The RTOG's research is primarily directed toward patients with brain tumors, head and neck cancer, lung cancer, gastrointestinal cancer, and genitourinal cancer. More limited research strategies have been developed for patients with gynecologic and breast cancer and sarcoma. RTOG research is supported by outstanding contributions from the Advanced Technology Integration, the Translational Research Program, and the Health Services Research and Outcomes Committees as well as the newly relocated Biospecimen Resource and from the four core committees of Medical Oncology, Medical Physics, Pathology, and Surgical Oncology. These contributions are well coordinated by a strong administrative and scientific infrastructure and have resulted in increased productivity in the current as compared with the prior funding cycle in terms of: 1. publication record; 2. clinical trials activated and completed; 3. overall patient accrual; 4. public and private funding of group research; 5. collaboration with other cooperative groups and other NIH-funded organizations;and 6. increased participation and leadership of Canadian investigators, with 8 of 37 full member institutions being Canadian. Close to two-thirds of all cancer patients receive radiation therapy for cure or for symptom relief. Novel technology, molecular targeted drugs and advances in radiation and cancer biology will improve the success rate of radiation therapy through clinical research over the next six years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA021661-37
Application #
8463801
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1979-02-20
Project End
2014-12-31
Budget Start
2013-03-04
Budget End
2014-12-31
Support Year
37
Fiscal Year
2013
Total Cost
$14,566,378
Indirect Cost
$3,822,459
Name
American College of Radiology
Department
Type
DUNS #
062485800
City
Reston
State
VA
Country
United States
Zip Code
20191
Woodward, Wendy A; Sneige, Nour; Winter, Kathryn et al. (2014) Web based pathology assessment in RTOG 98-04. J Clin Pathol 67:777-80
Pisansky, Thomas M; Pugh, Stephanie L; Greenberg, Richard E et al. (2014) Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. JAMA 311:1300-7
Hoffman, Karen E; Pugh, Stephanie L; James, Jennifer L et al. (2014) The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial. Qual Life Res 23:1841-58
Ang, K Kian; Zhang, Qiang; Rosenthal, David I et al. (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32:2940-50
Siegel, Erin M; Eschrich, Steven; Winter, Kathryn et al. (2014) Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum 57:941-57
Stanic, Sinisa; Paulus, Rebecca; Timmerman, Robert D et al. (2014) No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys 88:1092-9
Sperduto, Paul W; Shanley, Ryan; Luo, Xianghua et al. (2014) Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA). Int J Radiat Oncol Biol Phys 90:526-31
Rabinovitch, Rachel; Winter, Kathryn; Kuske, Robert et al. (2014) RTOG 95-17, a Phase II trial to evaluate brachytherapy as the sole method of radiation therapy for Stage I and II breast carcinoma--year-5 toxicity and cosmesis. Brachytherapy 13:17-22
Han, Baoguang; Yu, Menggang; Dignam, James J et al. (2014) Bayesian approach for flexible modeling of semicompeting risks data. Stat Med 33:5111-25
Hsu, I-Chow; Hunt, Daniel; Straube, William et al. (2014) Dosimetric analysis of radiation therapy oncology group 0321: the importance of urethral dose. Pract Radiat Oncol 4:27-34

Showing the most recent 10 out of 413 publications